| ALK | Anaplastic lymphoma kinase |
| AKT | protein kinase B |
| AUC | area under the curve |
| EGFR | Estimated glomerular filtration rate |
| ET | endocrine therapy |
| ER | estrogen receptor |
| 18F-FDG PET/CT | 18Fludeoxyglucose-Positron Emission Tomography/Computed Tomorgraphy |
| HR | Hazard ratio |
| HR | hormone receptor-positive |
| HER2 | Human epidermal growth factor receptor 2 |
| LR | long responder |
| LS | long survival |
| mBC | metastatic breast cancer |
| mTORC1 | mechanistic target of rapamycin complex 1 |
| NSAI | non-steroideal aromatase inhibitor |
| NSCLC | non small cell lung cancer |
| OS | overall survival |
| PFS | progression-free survival |
| PgR | Progesterone receptor |
| PI3K | phosphatidylinositol 3-kinase |
| PTEN | Phosphatase and tensin homolog |
| ROC | Receiver Operating Characteristic |
| SUV | standardized uptake volume |
| TKI | Tyrosine Kinase Inhibitor |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.